Carl Dambkowski Sells 5,500 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock

Apogee Therapeutics Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 5,500 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $132.74, for a total transaction of $730,070.00. Following the completion of the sale, the insider owned 177,873 shares in the company, valued at $23,610,862.02. This represents a 3.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Carl Dambkowski also recently made the following trade(s):

• On Monday, June 22nd, Carl Dambkowski sold 26,400 shares of Apogee Therapeutics stock. The shares were sold at an average price of $132.60, for a total value of $3,500,640.00.
• On Wednesday, June 3rd, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The stock was sold at an average price of $78.71, for a total value of $432,905.00.
• On Wednesday, May 6th, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The stock was sold at an average price of $84.14, for a total value of $462,770.00.

Apogee Therapeutics Price Performance

Shares of Apogee Therapeutics stock opened at $132.91 on Friday. The company has a market cap of $8.23 billion, a PE ratio of -30.70 and a beta of 0.32. Apogee Therapeutics Inc. has a 52 week low of $34.34 and a 52 week high of $133.85. The business has a 50 day moving average price of $93.59 and a 200-day moving average price of $82.02.

Apogee Therapeutics (NASDAQ:APGE) last announced its earnings results on Monday, May 11th. The company reported ($1.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.01. As a group, research analysts anticipate that Apogee Therapeutics Inc. will post -4.45 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on APGE shares. Rothschild & Co Redburn assumed coverage on shares of Apogee Therapeutics in a report on Friday, May 1st. They set a “buy” rating and a $140.00 price objective on the stock. TD Cowen downgraded shares of Apogee Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 23rd. Craig Hallum set a $135.11 price target on shares of Apogee Therapeutics and gave the company a “hold” rating in a research report on Monday, June 22nd. Wedbush cut shares of Apogee Therapeutics from an “outperform” rating to a “neutral” rating and set a $135.00 price target on the stock. in a report on Monday, June 22nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apogee Therapeutics in a research report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Apogee Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $121.25.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of APGE. Rockefeller Capital Management L.P. bought a new position in Apogee Therapeutics in the 4th quarter valued at $25,000. Los Angeles Capital Management LLC bought a new stake in shares of Apogee Therapeutics during the 4th quarter worth $37,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Apogee Therapeutics by 61.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 645 shares of the company’s stock worth $54,000 after buying an additional 246 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of Apogee Therapeutics in the 3rd quarter worth about $96,000. Finally, Seven Fleet Capital Management LP purchased a new position in shares of Apogee Therapeutics in the 4th quarter worth about $136,000. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.